Literature DB >> 18251696

Population-based impact of routine infant immunization with pneumococcal conjugate vaccine in the USA.

Carlos G Grijalva1, Marie R Griffin.   

Abstract

In the year 2000, a heptavalent pneumococcal conjugate vaccine (PCV7) was licensed and recommended for routine immunization of infants in the USA. During the following years, a number of studies documented the impact of this immunization program on rates of invasive pneumococcal disease, pneumonia and otitis media. This article aims to summarize current evidence on the population-based impact of this infant immunization program in the USA.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18251696     DOI： 10.1586/14760584.7.1.83

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN： 1476-0584            Impact factor:   5.217


  16 in total

1.  The stubborn persistence of adult pneumococcal pneumonia as a public health problem.

Authors:  Rosalind Hollingsworth; Raul Isturiz
Journal:  Hum Vaccin Immunother       Date:  2014-02-19       Impact factor: 3.452

Review 2.  Paediatric pneumococcal disease in Central Europe.

Authors:  R Prymula; R Chlibek; I Ivaskeviciene; A Mangarov; Zs Mészner; P Perenovska; D Richter; N Salman; P Simurka; E Tamm; G Tešović; I Urbancikova; V Usonis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-06-11       Impact factor: 3.267

3.  Respiratory infection and otitis media visits in relation to pneumococcal conjugate vaccine use in Saskatchewan.

Authors:  Ngoc-Hang Khuc; Ben Tan; Rosalie Tuchscherer; Nigel Sb Rawson; Philippe De Wals
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

Review 4.  Impact of pneumococcal conjugate vaccines on hospitalizations for pneumonia in the United States.

Authors:  Andrew D Wiese; Marie R Griffin; Carlos G Grijalva
Journal:  Expert Rev Vaccines       Date:  2019-03-20       Impact factor: 5.217

5.  Cost-effectiveness of polysaccharide pneumococcal vaccination in people aged 65 and above in Poland.

Authors:  Pawel Grzesiowski; Raquel Aguiar-Ibáñez; Aleksandra Kobryń; Laure Durand; Pierre-Emmanuel Puig
Journal:  Hum Vaccin Immunother       Date:  2012-10-01       Impact factor: 3.452

6.  Tolerability of two sequential electroporation treatments using MedPulser DNA delivery system (DDS) in healthy adults.

Authors:  Mark Wallace; Barbara Evans; Sandra Woods; Robin Mogg; Lei Zhang; Adam C Finnefrock; Dietmar Rabussay; Michael Fons; John Mallee; Devan Mehrotra; Florian Schödel; Luwy Musey
Journal:  Mol Ther       Date:  2009-03-10       Impact factor: 11.454

7.  Trends and seasonal variation in outpatient antibiotic prescription rates in the United States, 2006 to 2010.

Authors:  Katie J Suda; Lauri A Hicks; Rebecca M Roberts; Robert J Hunkler; Thomas H Taylor
Journal:  Antimicrob Agents Chemother       Date:  2014-03-03       Impact factor: 5.191

8.  Carriage of Streptococcus pneumoniae 3 years after start of vaccination program, the Netherlands.

Authors:  Judith Spijkerman; Elske J M van Gils; Reinier H Veenhoven; Eelko Hak; Ed P F Yzerman; Arie van der Ende; Alienke J Wijmenga-Monsuur; Germie P J M van den Dobbelsteen; Elisabeth A M Sanders
Journal:  Emerg Infect Dis       Date:  2011-04       Impact factor: 6.883

9.  Hospitalisation for lower respiratory tract infection in children in the province of Quebec, Canada, before and during the pneumococcal conjugate vaccine era.

Authors:  G Anderson; G Deceuninck; Z Zhou; F D Boucher; Y Bonnier Viger; R Gilca; P De Wals
Journal:  Epidemiol Infect       Date:  2017-08-14       Impact factor: 4.434

10.  Long-term effects of pneumococcal conjugate vaccine on nasopharyngeal carriage of S. pneumoniae, S. aureus, H. influenzae and M. catarrhalis.

Authors:  Judith Spijkerman; Sabine M P J Prevaes; Elske J M van Gils; Reinier H Veenhoven; Jacob P Bruin; Debby Bogaert; Alienke J Wijmenga-Monsuur; Germie P J M van den Dobbelsteen; Elisabeth A M Sanders
Journal:  PLoS One       Date:  2012-06-25       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.